

DAFTAR PUSTAKA

1. Kementerian Kesehatan Republik Indonesia. Komite Penanggulangan Kanker Nasional. Panduan Pentalaksanaan Kanker Kolorektal. 2015. [online] <http://kanker.kemkes.go.id/guidelines/PNPKkolorektal.pdf> [diakses 16 Mei 2021]
2. World Health Organization. Colorectal Cancer. International Agency for Research on Cancer. 2021. [online] <https://gco.iarc.fr/today/data/factsheets/cancers/8-Colon-fact-sheet.pdf> [diakses 20 Mei 2021]
3. World Health Organization. Indonesia. International Agency for Research on Cancer. 2021. [online] <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf> [diakses 20 Mei 2021]
4. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics. *CA Cancer J Clin.* 2019;69(5):363-85.
5. Fleming M, Ravula S, Tatishchev SF, and Wang HL. Colorectal carcinoma : Pathologic aspects. *J Gastrointest Oncol.* 2012;3(3):153-73.
6. Akkoca AN, Yanik S, Özdemir ZT, et al. TNM and Modified Dukes staging along with the demographic characteristics of patients with colorectal carcinoma. *Int J Clin Exp Med.* 2014;7(9):2828-35.
7. Amin MB. (Ed). 2010. *AJCC Cancer Staging Manual Seventh Edition.* Springer: Switzerland. p.143-64.
8. Portmann F. Carcinoma of the colon and rectum. *Am J Surg.* 1950;80(3):318-22.

9. Minhajat R. Kanker Kolorektal: Patofisiologi, Gambaran Klinis dan Histologi. 2017. UPT Unhas Press: Makassar. p.53-5.
10. Minhajat R, Saleh S, Harjianti T, et al. Profiles of endoglin and vascular endothelial growth factor based on staging and histological grading of colorectal cancer and their relationship with bevacizumab therapy. *J Coloproctol.* 2021;1(41): 1-108
11. Schulz WA. (Ed). 2005. *Molecular Biology of Human Cancers.* Springer: United State of America. Hamilton SR and Aaltonen LA.(Ed). 2000. *WHO Classification Tumours: Pathology and Genetics of Tumours of the Digestive System.* IARC Press: Lyon.p.105-19.
12. Bronchud MH, Foote MA, Giaccone G, et al. (Eds). 2008. *Principles of Molecular Oncology Third Edition.* Humana Press: New Jersey.p.239-51
13. Ribbati D and Vacca A. Overview of Angiogenesis during Tumor Growth. In: Figg WD and Folkman J. (Eds). *Angiogenesis: An Integrative Approach from Science to Medicine.* 2008. Springer: New York.p.161-66.
14. Kumar V, Abbas AK, and Aster JC. (Eds). 2013. *Robbins Basic Pathology.* Elsevier: Philadelphia.p.596-600.
15. Nussenbaum F and Herman IM. Tumor angiogenesis: insights and innovations. *J Oncol.* 2010; 132641.
16. Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. *Crit Rev Oncol Hematol.* 2007; 62(3): 179-213.
17. Kawamura H, Li X, Welsh M, et al. VEGF Signal Transduction in Angiogenesis. In: Figg WD and Folkman J. (Eds). *Angiogenesis: An*

Integrative Approach from Science to Medicine. 2008. Springer: New York.p.205-13.

18. Hashim AF, Al-Janabi AA, Mahdi LH, et al. Vascular endothelial growth factor (VEGF) receptor expression correlates with histologic grade and stage of colorectal cancer. *Libyan J Med.* 2010;5(1):1-4.
19. Bendardaf R, Buhmeida A, Hilska M, et al. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. *Anticancer Res.* 2008;28(6 B):3865-70.
20. Kekec Y, Paydas S, Zorludemir S, et al. Prognostic Significance of Vascular Endothelial Growth Factor-A Expression in Colorectal Cancer. *J.Cancer Mol.* 2006; 2(4):161-7.
21. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *J Clin Oncol.* 2006;24(33):5313-27.
22. Amin MB. (Ed). 2017. *AJCC Cancer Staging Manual Eighth Edition.* Springer: Switzerland. p.251-74.
23. Ferroni P, Palmirotta R, Spila A, et al. Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer. *Oncology.* 2007;71(3-4):176-84.
24. Marcio J, Jorge N, Habr-gama A. Anatomy and Embryology of the Colon , Rectum , and Anus. In: Wolff BG, Fleshman JW, Beck DE, et al. (Eds). *The ASCRS Textbook of Colon and Rectal Surgery.* 2007. Springer: New York. P.1-16.

25. Sakorafas GH, Zouros E, and Peros G. Applied vascular anatomy of the colon and rectum : Clinical implications for the surgical oncologist. *Surg Oncol.* 2006;15(4):243-55.
26. Mescher AL.(Ed). Digestive Tract: Large Intestine. In: *Basic Histology Junqueira Fourteenth Edition.* 2016. McGraw-Hill Education: United States. p.318-26.
27. Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. *Lancet.* 2019;394(10207):1467-80.
28. Brenner H, Kloor M, and Pox CP. Colorectal cancer. *Lancet.* 2014 Apr 26;383(9927):1490-502.
29. Sepulveda AR and Aisner DL. Molecular Basis of Diseases of the Gastrointestinal Tract. In: Coleman WB and Tsongalis GJ. *Essential Concepts in Molecular Pathology.* 2010. Elsevier: Oxford. P.248-60
30. Arnold CN, Goel A, Blum HE, et al. Molecular of colorectal cancer: Implications for molecular diagnosis. *Cancer.* 2005;104(10):2035-47.
31. Grady WM and Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. *Gastroenterology.* 2008 Oct;135(4):1079-99.
32. Dimova I, Popivanov G, and Djonov V. Angiogenesis in cancer – general pathways and their therapeutic implications. *J BUON.* 2014;19(1):15-21.
33. Arvelo F, Sojo F, and Cotte C. Tumour progression and metastasis. *Ecancermedicalscience.* 2016;10: 617.
34. Werther K, Christensen JJ, Brunner N et al. Soluble vascular endothelial growth factor levels in patients with primary coloractal carcinoma. *Eur J Surg*

Oncol. 2000;26:657-62.

35. Akbulut H, Altuntas F, Akbulut KG, et al. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with CRC. *Cytokine.* 2000; 20:184-90.
36. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful? *Clin Chem.* 2001;47(4):624-30.
37. Yeh CY, Hsieh PS, Chiang JM, et al. Preoperative carcinoembryonic antigen elevation in colorectal cancer. *Hepatogastroenterology.* 2011;58(109):1171-6.
38. Huang SH, Tsai WS, You JF, et al. Preoperative carcinoembryonic antigen as a poor prognostic factor in stage I-III colorectal cancer after curative-intent resection: a propensity score matching analysis. *Ann Surg Oncol.* 2019;26(6):1685-94.
39. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer: College of American Pathologists consensus statement 1999. *Arch Pathol Lab Med.* 2000;124(7):979-94.
40. Bramswig KH, Poettler M, Unseld M, et al. Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis. *Cancer Res.* 2013;73(22):6584-96.
41. Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guideline Version 1.2020 Colon Cancer. *NCCN.* 2020;90:347-56.
42. Rawla P, Sunkara T, and Barsouk A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. *Prz Gastroenterol.* 2019;14(2):89-103.

43. Werther K, Christensen IJ, Nielsen HJ, et al. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. *Br J Cancer*. 2002;86(3):417-23.
44. Pascual M, Alonso S, Salvans S, et al. The American Journal of Surgery Postoperative serum Vascular Endothelial Growth Factor is an independent prognostic factor of disease free survival and overall survival in patients with non metastatic colon cancer. *Am J Surg*. 2018;216:255–9.
45. Borda A, Prieto C, Jiménez J, et al. Prognostic value of preoperative carcinoembryogenic antigen: Is it useful in all stages of colorectal cancer? *Gastroenterol Hepatol*. 2016;39:191-8.
46. Hong Y, Kim J, Choi YJ, Kang JG. Clinical study of colorectal cancer operation: Survival analysis. *Korean J Clin Oncol*. 2020;16(1):3-8.